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Global Burden of Disease 2010 study considers migraine as one of the most
important noncommunicable diseases in the world, classifying it third in terms
of global prevalence (14.70%): it sums up the 54.19% of all the years of life
lived with disabilities caused by the rest of all neurological disorders. This
Editorial provides an historical excursus of old and new-entry molecules in
migraine therapeutic area. Drugs for acute treatment such as triptans date
back to the early 1990s with the appearance of sumatriptan and the following
six triptans in the years immediately after (zolmitriptan, rizatriptan, naratrip-
tan, eletriptan, almotriptan, frovatriptan). Prophylaxis drugs, dedicated to
patients with medium/high frequency of crises, show as last entries topira-
mate and botulinum toxin type A. The use of this preventative group, with
its intrinsic limits, is mandatory to reduce the risk of migraine chronification,
a highly harmful clinical phenomenon that produces as its natural conse-
quence the medication overuse headache. The development of new acute
and preventative compounds, such as 5HT (serotonin) 1F receptor (5-HT1F)
agonist lasmiditan, calcitonin gene related peptide (CGRP) peptide receptor
antagonists, anti-CGRP monoclonal antibodies (LY2951742, ALD403, LBR101)
and anti-CGRP-r monoclonal antibody (AMG334), is warranted and might be
soon completed in order to offer new opportunities to migraine patients.
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1. The burden of migraine
Global Burden of Disease (GBD) 2010 study considers migraine as one of the most
important noncommunicable diseases in the world, classifying it third in terms of
global prevalence (14.70%) right after dental caries in adults (35.29%) and
tension-type headache (20.77%). The same GBD 2010 study shows that migraine
alone, stratifying the diseases by using the term disability (health loss) evaluated
with years of life lived with disabilities (YLDs), sums up on its own the 54.19%
of all the YLDs caused by the rest of all neurological disorders [1]. This incredible
burden of headache disorders, ranked as leading cause of disability, has been calcu-
lated in the GBD 2010 study and is inserted into an overall increase of neurological
diseases of 12.4% compared with the previous study (GBD 1990), while migraine
alone showed an increase of 8.0% [1].
Furthermore, the calculus of the ictal disability, as short-term health loss relative
to the acute peak of the disease, classifies migraine seventh [2]. Lastly, if we refer to
the natural progression of migraine toward chronification we can calculate that
1 -- 4% of the general population suffers from chronic migraine, complicated by
medication overuse headache (MOH) [3]. This has been recently reported also in
the joint analysis of lifting the burden and WHO in the atlas of headache
disorders [4].
Considering this enormous epidemiological, social and economic impact of this
disease [5], testified also from the direct and indirect sanitary costs caused by it [6],
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it is before our eyes how the need to act is urgent, developing
pharmacological innovation in order to reduce this silent
plague.
2. Actual therapeutic options in migraine
Furthermore, going through an historical excursus of new-
entry molecules in migraine therapeutic area, it surprises
how old these molecules are [7,8].
Considering the drugs for acute treatment, the turning
point of the triptans introduction in the market dates back
to the early 1990s, with the appearance of the sumatriptan,
to which other six molecules followed in the years immedi-
ately after: zolmitriptan, rizatriptan, naratriptan, eletriptan,
almotriptan, frovatriptan [9-13]. All of them, even though their
pharmacokinetic properties were slightly different, had served
with honor in the past quarter of a century but if we consider
the overall positive cardiovascular risk--benefit safety
profile [14], we cannot understand the reason why only the
25% of migraine patients received prescription based on this
therapy [15].
On the other side of the therapeutic approach to migraine
we find prophylaxis. Recently, much importance has
been dedicated to the concept of prevention from migraine
chronification, a well-known and highly harmful clinical
phenomenon that produces as its natural consequence the
MOH, entrenching a refractoriness often very difficult to
eradicate [3,8].
On this line, migraine patients not responding to usual
prevention therapies gained advantages from the use of topir-
amate, a drug borrowed from other clinical areas like epi-
lepsy [16]. Unfortunately, such drug produces heavy side
effects and it is hard to manage for the general practitioner
who, seen the wideness of this phenomenon from an epidemi-
ological point of view, must be put in the position to manage
adequately not only the episodic but mostly medium/
high-frequency forms of migraine [16].
This would enormously reduce the inflow toward high-
specialization headache centers, reducing the alarming growth
of the chronic migraine population complicated with MOH
(1 -- 4%) [3,4].
Lastly, another application of old drugs re-applied to
migraine for serendipity deserves to be mentioned: botulinum
toxin type A, approved in the treatment of chronic
migraine [17], even though its exclusive hospital use and methods
of administration do not allow general practitioners that capillary
management of the disease WHO hopes for [4].
3. A call for new compounds in migraine
What is the message we can offer to the readers now? We hope
that on the basis of the existing pipelines for migraine
treatment, the development of these compounds might be
soon completed in order to offer new opportunities to
migraine patients.
Comforting results might come from 5-HT1F agonist
lasmiditan as alternative to triptans for migraine patients
with cardiovascular complications [8]. Since there has been
no new information on this drug in the past 2 years, we are
looking forward for future development, including the
availability of dose--response curves [18].
However, it is now clear that CGRP peptide receptor
antagonists, like olcegepant or telcagepant, despite of their
high efficacy have no future on the basis of their intravenous
administration or liver toxicity limits, to be considered how-
ever as ‘off-target effects’ [8]. It is also clear that for the pro-
phylaxis of episodic and chronic migraine, fully humanized
mAbs that target CGRP or its receptor seems to be promising:
starting 3 and 3b randomized controlled trials will clarify the
early clinical findings suggesting good tolerability and
efficacy.
Regarding this last point, the prevention as real central pil-
lar of migraine treatment, we hope that the above-mentioned
anti-CGRP monoclonal antibodies (LY2951742, ALD403,
LBR101) and anti-CGRP-r monoclonal antibody
(AMG334) might reach in due time the clinical use in order
to reduce the natural path to chronification of migraine [8].
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